Shira Cohen

3.5k total citations · 1 hit paper
70 papers, 2.5k citations indexed

About

Shira Cohen is a scholar working on Molecular Biology, Physiology and Oncology. According to data from OpenAlex, Shira Cohen has authored 70 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Molecular Biology, 18 papers in Physiology and 9 papers in Oncology. Recurrent topics in Shira Cohen's work include Adenosine and Purinergic Signaling (18 papers), Polyamine Metabolism and Applications (8 papers) and NF-κB Signaling Pathways (7 papers). Shira Cohen is often cited by papers focused on Adenosine and Purinergic Signaling (18 papers), Polyamine Metabolism and Applications (8 papers) and NF-κB Signaling Pathways (7 papers). Shira Cohen collaborates with scholars based in United States, Israel and Germany. Shira Cohen's co-authors include Pnina Fishman, Avivit Ochaion, Faina Barer, Sara Bar‐Yehuda, Aarne Raina, Dwight B. McNair Scott, Lea Rath‐Wolfson, S. Bar‐Yehuda, Linda A. Guarino and R. Patoka and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

Shira Cohen

69 papers receiving 2.3k citations

Hit Papers

The bases of the nucleic acids of some bacterial and anim... 1953 2026 1977 2001 1953 100 200 300 400

Peers

Shira Cohen
S Ohkuma Japan
Thomas H. Steinberg United States
Thomas W. Traut United States
Nigel Miller United Kingdom
Louann W. Murray United States
Jeehyeon Bae South Korea
S Ohkuma Japan
Shira Cohen
Citations per year, relative to Shira Cohen Shira Cohen (= 1×) peers S Ohkuma

Countries citing papers authored by Shira Cohen

Since Specialization
Citations

This map shows the geographic impact of Shira Cohen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shira Cohen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shira Cohen more than expected).

Fields of papers citing papers by Shira Cohen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shira Cohen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shira Cohen. The network helps show where Shira Cohen may publish in the future.

Co-authorship network of co-authors of Shira Cohen

This figure shows the co-authorship network connecting the top 25 collaborators of Shira Cohen. A scholar is included among the top collaborators of Shira Cohen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shira Cohen. Shira Cohen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Mejías, Asunción, et al.. (2021). Host transcriptional signatures as predictive markers of infection in children. Current Opinion in Infectious Diseases. 34(5). 552–558. 4 indexed citations
2.
Cohen, Shira, et al.. (2019). Discovery of small-molecule inhibitors targeting the ribosomal peptidyl transferase center (PTC) of M. tuberculosis. Chemical Science. 10(38). 8764–8767. 12 indexed citations
3.
Cohen, Shira & Pnina Fishman. (2019). <p>Targeting the A<sub>3</sub> adenosine receptor to treat cytokine release syndrome in cancer immunotherapy</p>. Drug Design Development and Therapy. Volume 13. 491–497. 27 indexed citations
4.
Cohen, Shira, et al.. (2019). Specific and label-free immunosensing of protein-protein interactions with silicon-based immunoFETs. Biosensors and Bioelectronics. 132. 143–161. 47 indexed citations
5.
Ilić, Stefan, Shira Cohen, Ariel Afek, et al.. (2019). DNA Sequence Recognition by DNA Primase Using High-Throughput Primase Profiling. Journal of Visualized Experiments. 2 indexed citations
6.
Ohana, Gil, Shira Cohen, Lea Rath‐Wolfson, & Pnina Fishman. (2016). A3 adenosine receptor agonist, CF102, protects against hepatic ischemia/reperfusion injury following partial hepatectomy. Molecular Medicine Reports. 14(5). 4335–4341. 26 indexed citations
7.
Fishman, Pnina & Shira Cohen. (2016). The A3 adenosine receptor (A3AR): therapeutic target and predictive biological marker in rheumatoid arthritis. Clinical Rheumatology. 35(9). 2359–2362. 52 indexed citations
8.
Fishman, Pnina, Shira Cohen, & Sara Bar‐Yehuda. (2013). Targeting the A3 adenosine receptor for glaucoma treatment (Review). Molecular Medicine Reports. 7(6). 1723–1725. 25 indexed citations
9.
Cohen, Shira, Salomon M. Stemmer, Avivit Ochaion, et al.. (2010). CF102 an A3 adenosine receptor agonist mediates anti‐tumor and anti‐inflammatory effects in the liver. Journal of Cellular Physiology. 226(9). 2438–2447. 73 indexed citations
10.
Hurevich, Mattan, Shira Cohen, Christian Devaux, et al.. (2010). Rational conversion of noncontinuous active region in proteins into a small orally bioavailable macrocyclic drug-like molecule: The HIV-1 CD4:gp120 paradigm. Bioorganic & Medicinal Chemistry. 18(15). 5754–5761. 10 indexed citations
11.
Ochaion, Avivit, S. Bar‐Yehuda, Shira Cohen, et al.. (2009). The anti-inflammatory target A3 adenosine receptor is over-expressed in rheumatoid arthritis, psoriasis and Crohn’s disease. Cellular Immunology. 258(2). 115–122. 104 indexed citations
12.
Bar‐Yehuda, S., Lea Rath‐Wolfson, Luis Del Valle, et al.. (2009). Induction of an antiinflammatory effect and prevention of cartilage damage in rat knee osteoarthritis by CF101 treatment. Arthritis & Rheumatism. 60(10). 3061–3071. 107 indexed citations
13.
Stemmer, Salomon M., Lea Madi, David Castel, et al.. (2008). CF102 an A3 adenosine receptor agonist induces in vivo apoptosis of Hepatocellular carcinoma. Cancer Research. 68. 5712–5712.
14.
Ochaion, Avivit, S. Bar‐Yehuda, Shira Cohen, et al.. (2008). The A3 adenosine receptor agonist CF502 inhibits the PI3K, PKB/Akt and NF-κB signaling pathway in synoviocytes from rheumatoid arthritis patients and in adjuvant-induced arthritis rats. Biochemical Pharmacology. 76(4). 482–494. 60 indexed citations
15.
Fishman, Pnina, Kenneth A. Jacobson, Avivit Ochaion, Shira Cohen, & S. Bar‐Yehuda. (2007). The Anti-Cancer Effect of A3 Adenosine Receptor Agonists: A Novel, Targeted Therapy. Immunology Endocrine & Metabolic Agents - Medicinal Chemistry. 7(4). 298–303. 19 indexed citations
16.
Bar‐Yehuda, Sara, Michael H. Silverman, William Kerns, et al.. (2007). The anti-inflammatory effect of A3adenosine receptor agonists: a novel targeted therapy for rheumatoid arthritis. Expert Opinion on Investigational Drugs. 16(10). 1601–1613. 77 indexed citations
17.
Fishman, Pnina, Sara Bar‐Yehuda, Lea Madi, et al.. (2006). The PI3K–NF-κB signal transduction pathway is involved in mediating the anti-inflammatory effect of IB-MECA in adjuvant-induced arthritis. Arthritis Research & Therapy. 8(1). R33–R33. 79 indexed citations
18.
Genovese, Mark C., Shira Cohen, D E Furst, et al.. (2001). Safety Of Combination Therapy With Anakinra And Etanercept In Patients With Rheumatoid Arthritis.. Arthritis & Rheumatism. 44(9). 23 indexed citations
19.
Ramakrishna, S. Anantha, Linda A. Guarino, & Shira Cohen. (1978). Polyamines of Anacystis nidulans and metabolism of exogenous spermidine and spermine. Journal of Bacteriology. 134(3). 744–750. 24 indexed citations
20.
Plunkett, William & Shira Cohen. (1975). Potentiation of analogs of adenosine by an inhibitor of adenosine deaminase. Proceedings of the American Association for Cancer Research. 16(66). 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026